Tampere University of Technology

TUTCRIS Research Portal

A model to estimate the outcome of prostate cancer photodynamic therapy with TOOKAD soluble WST11

Research output: Contribution to journalArticleScientificpeer-review

Details

Original languageEnglish
Pages (from-to)4771-4783
Number of pages13
JournalPhysics in Medicine and Biology
Volume56
Issue number15
DOIs
Publication statusPublished - 7 Aug 2011
Publication typeA1 Journal article-refereed

Abstract

Interstitial photodynamic therapy is becoming an interesting modality to treat some early stage prostate cancers. A light-sensitive drug is injected to the patient and activated by light using optical fibres inserted inside the prostate. In this work, we were interested in the characterization of the light action model for the WST11 (Tookad Soluble) drug. A retrospective analysis was performed on results from 28 patients enrolled in phase I and II trials with the WST11 drug. A drug dose of 4 mg/kg patient, dose light of 200 J cm-1 and wavelength of 753 nm were used. Correlation between the illuminated volume and the obtained necrosis, measured at day 7 MR images, was clearly established. This result suggests that photodynamic therapy planning is possible based on this model.